{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:11:55Z","timestamp":1770509515853,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T00:00:00Z","timestamp":1274313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10792-010-9372-1","type":"journal-article","created":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T04:52:44Z","timestamp":1274244764000},"page":"577-581","source":"Crossref","is-referenced-by-count":36,"title":["Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et\u2019s disease after withdrawal of infusions"],"prefix":"10.1007","volume":"30","author":[{"given":"Alfredo","family":"Ad\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pelegrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,20]]},"reference":[{"key":"9372_CR1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251\u2013259","journal-title":"Cytokine"},{"key":"9372_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikafis","year":"2001","unstructured":"Sfikafis PP, Theodossiadis PG, Katsiari CG, Kahlamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuevitis in Beh\u00e7et\u2019s disease. Lancet 358:295\u2013296","journal-title":"Lancet"},{"key":"9372_CR3","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of inflximab in the treatment of uveitis that is resistant to treatment with combination of azathioprine, cyclosporine and corticosteroid in Beh\u00e7et disease; an open-label trial. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"9372_CR4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","volume":"358","author":"S Munoz-Hernandez","year":"2001","unstructured":"Munoz-Hernandez S, Hidalgo V, Fern\u00e1ndez-Mel\u00f3n J, Schlincker A, Martin-Mola E (2001) Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:1644","journal-title":"Lancet"},{"key":"9372_CR5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","volume":"19","author":"JM Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E et al (2005) Long-term treatment of refractory posterior uveitis with anti-TNF-\u03b1 (infliximab). Eye 19:841\u2013845","journal-title":"Eye"},{"key":"9372_CR6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","volume":"33","author":"S Hale","year":"2006","unstructured":"Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33:231\u2013237","journal-title":"Cytokine"},{"key":"9372_CR7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A Galor","year":"2006","unstructured":"Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113:2317\u20132323","journal-title":"Ophthalmology"},{"key":"9372_CR8","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1362\u20131368","journal-title":"J Rheumatol"},{"key":"9372_CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti P (2007) Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 51:191\u2013196","journal-title":"Jpn J Ophthalmol"},{"key":"9372_CR10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1196\/annals.1361.095","volume":"1051","author":"S Tognon","year":"2005","unstructured":"Tognon S, Graziani G, Marcolongo R (2005) Anti-TNG-alpha therapy in seven patients with Beh\u00e7et\u2019s uveitis: advantages and controversial aspects. Ann NY Acad Sci 1051:506\u2013514","journal-title":"Ann NY Acad Sci"},{"key":"9372_CR11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"KF Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol 146:845\u2013850","journal-title":"Am J Ophthalmol"},{"key":"9372_CR12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Nicoli","year":"2007","unstructured":"Nicoli L, Nannini C, Benucci M, Chindamo D et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology 46:1161\u20131164","journal-title":"Rheumatology"},{"key":"9372_CR13","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/art.22718","volume":"56","author":"AE Bijl van der","year":"2007","unstructured":"van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, Allaart CF, Breedveld FC, Dijkmans BA (2007) Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56:2129\u20132134","journal-title":"Arthritis Rheum"},{"key":"9372_CR14","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3748\/wjg.v13.i39.5238","volume":"13","author":"R Caviglia","year":"2007","unstructured":"Caviglia R, Ribolsi M, Rizi M, Emerenziati S, Annunziata ML, Cicala M (2007) Maintenance of remission with infliximab in inflammatory bowel disease: effficacy and safety long-term follow-up. World J Gastroenterol 13:5238\u20135244","journal-title":"World J Gastroenterol"},{"key":"9372_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O\u2019Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27\u201335","journal-title":"Arthritis Rheum"},{"key":"9372_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A (2005) Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et disease. Int Ophthalmol 26:83\u201392","journal-title":"Int Ophthalmol"},{"key":"9372_CR17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","volume":"138","author":"NN Markomichelakis","year":"2004","unstructured":"Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648\u2013650","journal-title":"Am J Ophthalmol"},{"key":"9372_CR18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","volume":"24","author":"M Diaz-Llopis","year":"2008","unstructured":"Diaz-Llopis M, Garc\u00eda-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24:351\u2013361","journal-title":"J Ocul Pharmacol Ther"},{"key":"9372_CR19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Sabed T, Situnayake RD, Murria PI (2007) Adalimumab for sight-threating uveitis in Beh\u00e7et\u2019s disease. Eye 21:824\u2013825","journal-title":"Eye"},{"key":"9372_CR20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","volume":"66","author":"JAM Laar van","year":"2007","unstructured":"van Laar JAM, Mossotten T, van Daele PLA, Jamnitski A, Baarsma GS, van Hagen PM (2007) Adalimumab: a new modality for Beh\u00e7et\u2019s disease? Ann Rheum Dis 66:565\u2013566","journal-title":"Ann Rheum Dis"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-010-9372-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-010-9372-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-010-9372-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T20:30:22Z","timestamp":1559248222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-010-9372-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,20]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["9372"],"URL":"https:\/\/doi.org\/10.1007\/s10792-010-9372-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,20]]}}}